Skip to main content

Advertisement

SpringerLink
Log in

One size does not fit all: quality of life during adjuvant aromatase inhibitor therapy

  • Invited Commentary
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

The Original Article was published on 07 September 2010

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Early Breast Cancer Trialists’ Collaborative Group (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687–1717

    Article  Google Scholar 

  2. Burstein HJ, Prestrud AA, Seidenfeld J, Anderson H, Buchholz TA, Davidson NE, Gelmon KE, Giordano SH, Hudis CA, Malin J et al (2010) American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol 28:3764–3796

    Google Scholar 

  3. Winer EP, Hudis C, Burstein HJ, Wolff AC, Pritchard KI, Ingle JN, Chlebowski RT, Gelber R, Edge SB, Gralow J et al (2005) American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol 23:619–629

    Google Scholar 

  4. Chlebowski RT, Geller ML (2006) Adherence to endocrine therapy for breast cancer. Oncology 71:1–9

    CAS  PubMed  Google Scholar 

  5. Barron TI, Connolly R, Bennett K, Feely J, Kennedy MJ (2007) Early discontinuation of tamoxifen: a lesson for oncologists. Cancer 109:832–839

    Article  CAS  PubMed  Google Scholar 

  6. Partridge AH, LaFountain A, Mayer E, Taylor BS, Winer E, Asnis-Alibozek A (2008) Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer. J Clin Oncol 26:556–562

    Article  CAS  PubMed  Google Scholar 

  7. Hershman DL, Kushi LH, Shao T, Buono D, Kershenbaum A, Tsai WY, Fehrenbacher L, Gomez SL, Miles S, Neugut AI (2010) Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. J Clin Oncol, epub June 28, 2010

  8. Crew KD, Greenlee H, Capodice J, Raptis G, Brafman L, Fuentes D, Sierra A, Hershman DL (2007) Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. J Clin Oncol 25:3877–3883

    Article  PubMed  Google Scholar 

  9. Henry NL, Giles JT, Ang D, Mohan M, Dadabhoy D, Robarge J, Hayden J, Lemler S, Shahverdi K, Powers P et al (2008) Prospective characterization of musculoskeletal symptoms in early stage breast cancer patients treated with aromatase inhibitors. Breast Cancer Res Treat 111:365–372

    Article  CAS  PubMed  Google Scholar 

  10. Mao JJ, Stricker C, Bruner D, Xie S, Bowman MA, Farrar JT, Greene BT, Demichele A (2009) Patterns and risk factors associated with aromatase inhibitor-related arthralgia among breast cancer survivors. Cancer 115:3631–3639

    Article  CAS  PubMed  Google Scholar 

  11. Thomas R, Godward S, Makris A, Bloomfield D, Moody AM, Williams M (2004) Giving patients a choice improves quality of life: a multi-centre, investigator-blind, randomised, crossover study comparing letrozole with anastrozole. Clin Oncol (R Coll Radiol) 16:485–491

    CAS  Google Scholar 

  12. Briot K, Tubiana-Hulin M, Bastit L, Kloos I, Roux C (2010) Effect of a switch of aromatase inhibitors on musculoskeletal symptoms in postmenopausal women with hormone-receptor-positive breast cancer: the ATOLL (articular tolerance of letrozole) study. Breast Cancer Res Treat 120:127–134

    Article  CAS  PubMed  Google Scholar 

  13. Sestak I, Cuzick J, Sapunar F, Eastell R, Forbes JF, Bianco AR, Buzdar AU (2008) Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis. Lancet Oncol 9:866–872

    Article  PubMed  Google Scholar 

  14. Partridge AH, Ades T, Spicer P, Englander L, Wickerham DL (2007) Helping breast cancer patients adhere to oral adjuvant hormonal therapy regimens. Commun Oncol 4:725–731

    Google Scholar 

Download references

Conflicts of interest

NLH receives research funding from AstraZeneca and Eli Lilly. VS receives research funding from Pfizer and Novartis and has received honoraria from AstraZeneca.

Author information

Authors and Affiliations

  1. 300 North Ingalls, Room 3A04, Ann Arbor, MI, 48109-5419, USA

    N. Lynn Henry

  2. Bunting-Blaustein Cancer Research Building, 1650 Orleans Street, Room 145, Baltimore, MD, 21231-1000, USA

    Vered Stearns

Authors
  1. N. Lynn Henry
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Vered Stearns
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to N. Lynn Henry.

Additional information

This is an invited commentary to article doi: 10.1007/s10549-010-1091-9.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Henry, N.L., Stearns, V. One size does not fit all: quality of life during adjuvant aromatase inhibitor therapy. Breast Cancer Res Treat 125, 751–753 (2011). https://doi.org/10.1007/s10549-010-1206-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-010-1206-3

Keywords

Search

Navigation